Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan

Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock on April 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Derek Maetzold, the President and CEO of Castle Biosciences, sold shares of the company's common stock on April 12, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2023.
• A total of 1,947 shares were sold directly at a weighted-average price of $20.35, with individual transaction prices ranging from $20.05 to $20.72.
• Additional shares were sold indirectly through various trusts for the benefit of Maetzold's family members, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several Maetzold 2018 Remainder Trusts.
• Following the reported transactions, Maetzold directly owns 65,418 shares and indirectly owns shares through various trusts.
• The reporting person has undertaken to provide full information regarding the number of shares and prices at which the transaction was effected, upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing 10b5-1 plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

Insider trading activity is closely monitored in the biotech industry, as it can provide insights into management's perspective on the company's future prospects. However, sales under pre-arranged plans are common and don't necessarily indicate a negative outlook.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates